Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2008-12-18

Clinical Trial Update: A Study to Determine the Safety and Efficacy of Atralin (Tretinoin 0.05%) Gel for the Treatment of Rosacea [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating Atralin (tretinoin 0.05% gel) for rosacea has completed, assessing safety and efficacy in affected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Atralin (tretinoin)

Snippet

Sponsor: Coria Laboratories, Ltd. | Conditions: Rosacea | Phase 2 | Status: COMPLETED